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Background and Objectives. So far several reports
have described changes in the expression of surface
antigens in progenitor cells and blasts following cry-
opreservation. However, there are no data on the
effects of cryopreservation on the expression of the
three CD34 epitope classes, and on their relation-
ship with the clonogenic capacity of PBPC collected
by leukapheresis. 
Design and Methods. In order to analyze the effects
of freezing/thawing procedures (–80°C storage for 3
months) and use of dimethylsulfoxide (DMSO) on the
immunophenotype profile and colony production of
peripheral blood progenitor cells (PBPC) in apheresis
products derived from 20 patients with stage 0-III
non-Hodgkin’s lymphoma (nHL), a flow cytometry
study was undertaken using different CD34 mono-
clonal antibodies (MoAbs) capable of recognizing the
3 epitope classes of CD34 molecule (class III: HPCA-
2/FITC, HPCA-2/PE, 581/FITC, 581/PE; class II: Q-
Bend 10/PE; class I: ICH3/PE, BI3C5-PE, Immu-133-
PE). CD34 epitope expression was also analyzed in
thawed CD34+ blasts obtained from 14 patients with
acute myeloid leukemia (AML), who were analyzed
using a larger number (#17) of CD34 epitope class I,
II, and III reactive MoAbs.
Results. Under our experimental conditions it was
found that class III and class II CD34 epitopes (dif-
ferentially resistant to enzymatic cleavage with neu-
raminidase, chymopapain and glycoprotease) are bet-
ter preserved than class I epitope – sensitive to
degradation – after cell exposure to cryoprotectant
DMSO and the freezing- thawing procedures. Results
further showed a concomitant decrease in class I
CD34+ counts and in BFU-E colony production. A sig-
nificant increase in CD34 antigen expression levels
(i.e. antibody binding capacity, ABC) by cryopre-
served cells stained with CD34 epitope class III, and
class II reactive MoAbs was also documented, while
no changes after cryopreservation was noted using
class I-reactive MoAbs. The slight increase in the per-
centage of CD34+ cells detected after frozen storage
was correlated to a concomitant decrease in the
number of more mature myeloid cells (CD15+, CD13+,
CD33+). Compared to pre-cryopreservation values, a
slight reduction in class I CD34 epitope expression
was also found in thawed CD34+ AML blasts.
Interpretation and Conclusions. As far as the reduc-
tion of class I CD34 epitope is concerned, it may be
hypothesized that the freezing procedure, use of
DMSO, and/or lysis methodology may either damage
a CD34 subset, or induce distinct alterations of the
CD34 glycoprotein, possibly determining a reduction
in their immunoreactivity with some CD34 MoAbs. In
conclusion, this study has shown that exposure to
the cryoprotectant DMSO and the freezing/thawing
procedures modifies the distribution of CD34 epitopes
as well as the clonogenic capacity of PBPCs from nHL
patients, and CD34+ blasts from AML. These findings
need to considered when selecting CD34 MoAbs for
enumeration and positive selection of stem/progeni-
tor cells for research and clinical purposes.
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The CD34 molecule is a one-pass transmem-brane glycoprotein with a molecular weight of105-120 kilodalton in either the reduced or
unreduced form. The full length CD34 protein is com-
posed of 385 amino acids, and contains nine sites for
N-glycosylation and a number of sites for O-glycosy-
lation, that are essential constituents of the three epi-
topes of the molecule.1-3 More recently, a truncated
form of CD34 protein has been characterized, which
contains only 323 amino acids. While the intracellu-
lar cytoplasmic domain is shorter in the CD34 splice
variant, the extracellular and the transmembrane
regions of the two forms of CD34 are identical.4,5
CD34 is also rich in sialic acid, and its biochemical
composition suggests a mucin-like structure and
resembles in some respects leucosialin (CD43).1-5
CD34 antigen is expressed on hemopoietic stem
and progenitor cells, small vessel endothelial cells,
and a subset of fibroblasts. Seven CD34 MoAbs have
been clustered at the 3rd and 4th Workshop on Leukocyte
Differentiation Antigens (Oxford, 1986 and Vienna,
1988), and a further 25 MoAbs were verified as rec-
ognizing the CD34 molecule during the 5th and the 6th
International Workshops on Leukocyte Differentiation Anti-
gens (Boston, 1983; Osaka, 1996), the most direct evi-
dence being reactivity with cells transfected with CD34
cDNA and binding to CD34 protein.2-5 Based on cur-
rent knowledge, the epitope specificity of CD34
MoAbs could be classified into three distinct groups
according to the different sensitivities of the epitopes
to enzymatic cleavage (which has been performed
using neuraminidase, chymopapain and glycopro-
tease), reactivity with fibroblasts and high endothelial
venules, and cross-blocking experiments.2,5,6 We know,
in fact, that glycoprotease from Pasteurella haemolytica
specifically cleaves only proteins containing sialylated
O-linked glycans, while neuraminidase cleaves sialic
acid residues. On the basis of these data, it can be
speculated that class III epitopes are more proximal to
the extracellular side of the cell membrane than the
class I and class II epitopes.6
Over the few last years, PBPC have been increas-
ingly used to provide rapid and durable hemopoiet-
ic reconstitution following high dose chemo- and
radiotherapy.7 However, the quality of PBPC aphere-
sis products has to be monitored in all the process-
ing steps, which include cryopreservation, and sub-
sequent thawing and reinfusion. Traditionally, either
the CFU-GM test or flow cytometry measurement of
CD34-expressing cells has been used to evaluate the
potential of PBPC autografts for restoring hemato-
poiesis after high-dose therapy.8,9 There are accumu-
lating data showing a significant correlation between
numbers of transplanted CD34+ cells/kg and hemo-
poietic reconstitution.10 So far several studies have
investigated the effects of cryopreservation on the
expression of surface antigens in progenitor cells and
blasts. Most of the data have focused on the analy-
sis of CD7, CD13, CD33 and CD34 molecules dur-
ing the freezing/thawing procedures in the presence
of cryoprotectants such as DMSO.11-17 However,
there are no data on the effects of cryopreservation
on the distribution of expression of CD34 epitopes or
on its relationship with the clonogenic capacity of
PBPC collected by leukapheresis. 
In order to analyze the effects of short-term cryo-
preservation (3 months at –80°C using 10% DMSO
and 4% human serum albumin as a cryoprotective
agent without rate-controlled freezing) on the
immunophenotype profile and colony production of
PBPC apheresis products from 20 patients with stage
0-III non-Hodgkin’s lymphoma (nHL), a flow cytom-
etry study was undertaken using different CD34
MoAbs capable of recognizing the 3 epitope classes
of CD34 molecule. The effect of cryopreservation on
the expression of different CD34 epitopes was also
evaluated through the use of a flow cytometer and 17
distinct CD34-reactive MoAbs on CD34+ (HPCA-2+)
blasts taken from 14 patients with acute myeloid
leukemia (AML).
Design and Methods
Subjects 
Non-Hodgkin’s lymphoma. Fresh and cryopreserved
peripheral blood mononuclear cells (PBMNC)
obtained from 20 consecutive patients with stage 0-
III nHL (aged between 16 and 56; mean: 35 years)
were investigated within 1 hour from their collection
and processing. Diagnosis of lymphoma was based
on morphologic, immunologic, cytochemical, cyto-
genetic, and molecular genetic criteria. No bone mar-
row contamination of lymphoma cells was docu-
mented at the time of the study. All patients achieved
a remission state at the time of PBMNC collection.
The mobilization regimen was cyclophosphamide 7
g/m2 plus rhG-CSF (filgrastim, 5-15 µg/kg/day).
PBMNC were collected by apheresis. Written
informed consent for PBPC collection and autolo-
gous transplantation was obtained from each patient.
Acute myeloid leukemia. Light density (< 1.077 g/mL)
peripheral blood cells obtained from 14 patients with
CD34+ (HPCA-2/PE) AML were investigated before
and after cryopreservation. Diagnosis of leukemia
was based on morphologic, cytochemical, cytoge-
netic, molecular genetic, and immunologic criteria.
According to the FAB classification, the distribution
of AML subtypes was as follows: M0: 1pt; M1: 5 pts;
M2: 5 pts; M4 3. AML patients had a blast percent-
age higher than 60% in all specimens analyzed (mean
74%). The CD34+ acute leukemia samples included in
this study were selected using the HPCA-2-PE
MoAb.18,19 Using HPCA-2/PE MoAb, the range of
CD34 positivity on leukemic cells was 45-82%. AML
patients were treated with a DAT (daunorubicin, cyto-
sine arabinoside, thioguanine)-based induction regi-
men, followed by consolidation chemotherapy.
Collection of PBPC, processing and
cryopreservation
PBMNC were collected by apheresis from nHL
patients in remission state during hematologic recov-
ery which followed the mobilization regimen adminis-
tered (cyclophosphamide 7 g/m2 plus rhuG-CSF (fil-
grastim, 5-15 µg/kg/day). PBPC were collected by
means of apheresis using CS-300 Plus blood cell sep-
arator (Omnix TM, Baxter, Milan, Italy). Each aphere-
sis session consisted in processing 10-15 liters of
blood. Acid citrate-dextrose (ACD) was used as anti-
coagulant. Samples were collected immediately after
apheresis and analyzed by flow cytometry with satu-
rating concentrations of CD34 MoAbs and irrelevant
isotype-matched MoAbs.
Peripheral blood mononuclear cell samples were
mixed with an equal volume of cryoprotective solu-
tion consisting of 20% DMSO and 8% human serum
albumin. The final cell concentration was adjusted to
< 50109/L. The suspensions were frozen in cryo-
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preservation bags (Cryocyte freezing container, Bax-
ter) without rate-controlled freezing in an electrical
freezer at –80°C (Haraeus-Votsch).
Twenty specimens from each donor were stored for
3 months in order to study the effect of cryopreser-
vation on the immunophenotypic profile of stem-
progenitor cells.
For rapid thawing, freezing tubes were taken from
the freezer and placed in a 37°C water bath, they
were then diluted slowly 10 fold with a calcium- and
magnesium-deprived PBS buffer. Samples were also
taken from freezing tubes, before and after cryo-
preservation, for trypan blue dye exclusion tests.
Cell counting and leukocyte differential was per-
formed using an automated hematology analyzer
(Technicon H3, Bayer, Milan). The white cell differ-
ential was also determined microscopically on May-
Grünwald-Giemsa stained films.
Flow cytometry analysis of class I, II, and III
CD34 epitopes
PBMC apheresis products and light density cells
obtained from AML samples were analyzed before and
after cryopreservation with a Facscan flow cytometer
(Becton Dickinson, San Josè, CA, USA) equipped with
a 15 mW argon-ion laser. The instrument was cali-
brated with FITC (fluorescein isothyocyanate) and PE
(R- phycoerythrin) beads provided by Becton Dickin-
son. Data were analyzed with negative controls using
Lysis II and Cell Quest research software. As negative
control, we used an appropriate and similarly titered
isotype control.20 Over 50,000 viable cells (contain-
ing at least 100 CD34+ cells) were analyzed for each
sample at a flow rate of approximately 300 particles
per second.
The enumeration and the quantitative analysis of
the expression levels of the various CD34+ MoAbs was
performed on fresh and cryopreserved PBMNC
apheresis products using a modified version of the
Milan protocol.8 This is a no-lyse and wash, dual plat-
form technique based on direct CD34 immunofluo-
rescence and assessment of leukocyte absolute counts
using a separate electronic counter (Techicon H3, Bay-
er). Erythrocytes were lysed by NH4Cl Ortho-mune
lysing solution, according to the manufacturer’s
instructions. Viable cells were identified using a nucle-
ic acid dye, as described in detail later on.
Since the ABC calculation for cell samples stained
simultaneously with CD34 and CD45 MoAbs was
unreliable (data not shown), we decided to follow
the Milan protocol instead of the ISHAGE method,
which is known to provide better results for the analy-
sis  of CD34+ cells in some samples. However, the
concomitant use of CD34 MoAbs and a nucleic acid
dye significantly improved the sensitivity and speci-
ficity of our method.
The CD34 assay used in this study consisted of the
following steps:
1. nucleated cells were distinguished from unlysed
erythrocytes, debris and platelets by their relatively
high FSC (forward scatter) signals (gate R 1). Pro-
pidium iodide as a nucleic acid dye was used to
select nucleated cells during data analysis and
counting the number of dead cells. CD34 class I,
II and III reactive MoAbs were counterstained with
propidium iodide to identify the number of
CD34+ cells positive for the nucleic acid dye. For
the analysis of CD34 PE-conjugates, we used 7-
amino-actinomycin-D (7-ADD) as a nucleic acid
dye. This compound has been shown to be useful
in the discrimination of live versus dead cells in a
multiparametic analysis;22
2. the gated viable cells were then analyzed for their
CD34 expression by looking at the dot plot gen-
erated by combining the side scatter (SSC) para-
meter and fluorescence 1 or 2, as appropriate
(gate R2);
3. the events included in gate R1 and R2 were then
displayed on the dot plot, forward scatter vs side
scatter, to verify that the light scatter characteris-
tics of the CD34+ cell cluster were typical for
stem/progenitor cells;
4. an isotype control MoAb was used to set the
marker discriminating between positive and neg-
ative fluorescence signals. The percentage value
of positive events of the isotype control was sub-
tracted from the CD34+ counts.
Flow cytometry data were expressed as percentage
of positivity (using the standard marker approach),
as antibody binding capacity (ABC) units, or as mol-
ecules of equivalents of soluble fluorochromes
(MESF) values.18,24
Based on the analysis of the minimum detection
threshold of our flow cytometer, and on variation in
ABC values for CD34 MoAbs in the specimens ana-
lyzed (evaluated within and between different speci-
mens), we estimated that the lower limit of quantifi-
cation was between 0.5-0.7103 MESF/cell (indirect
staining) and between 0.9-1.1103 ABC/cell. Below
this limit the enumeration of antigenic determinants
was considered unreliable and not reproducible.18
Monoclonal antibodies to CD34 
A large series of CD34 epitope class I, II, and III reac-
tive MoAbs were used in this study. PBMNC apheresis
products from nHL were investigated by using 6 dif-
ferent CD34 MoAbs: HPCA-2/FITC (class III, BDis),
HPCA-2/PE (BDis), 581-FITC (class III, Caltag),
581/PE (Caltag), Q-Bend 10-PE (class II, Immuno-
tech); ICH3-PE (class I, Caltag), Immu-133 (class I,
immunotech). For the analysis of class I, and class II
CD34 epitopes, we used only PE conjugates, since
recent data have indicated that FITC-labeled class I
and class II CD34 MoAbs provide less reliable results
than the PE-conjugated forms.25-27
The expression of CD34 on leukemic cells was
assessed by using 17 different unconjugated CD34
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MoAbs (Class I: Immu-133, Immu-409, 14G3,
BI3C5; Class II: Q-Bend 10, 43A1, MD34.1,
MD34.3, MD34.2, 4A1, 9066, 9069; Class III:
CD34-9F2, 8G12, 581, 553, 563). This series of
CD34  MoAbs was provided by Prof. M. Greaves
(London, UK), and were intended for analysis during
the fifth Workshop on Leukocyte Differentiation Antigens
held in Boston, November 1993.2,4
Negative controls were used in all experiments. As
negative controls, appropriate and similarly titered
isotype-matched non-relevant MoAbs (mouse IgG1,
IgG2a, IgM; Dakopatts, Silenus, Becton, Caltag)
were employed. Light density cells from AML sam-
ples were washed twice in PBS before their incubation
with CD34 MoAbs. Human AB serum was added pri-
or to antibody incubation to avoid non-specific bind-
ing of MoAbs to Fc receptors. All samples were fur-
ther incubated for 20 minutes with a lysing buffer
(Facslysing solution, Becton Dickinson) to eliminate
red blood cells.
Purified CD34 MoAbs (including the isotype con-
trols) were utilized using an indirect immunofluores-
cence technique. As a second step we employed FITC-
conjugated goat F(ab’) Ig fragments specific for mouse
Ig (fluorochrome/protein ratio: 2.3 (Dakopatts).20
ABC calculation (direct immunofluorescence)
To evaluate the number of antigenic determinants
per cell for the different CD34 MoAbs, we used
Quantum Simply Cellular Beads (Flow Cytometry
Standard Corp., purchased from Walter Occhiena
srl, Turin, Italy). Quantum Simply Cellular is a mixture
of four highly uniform microbead populations of the
same size which have varying capacities to bind
mouse monoclonal IgG antibodies. A blank popula-
tion of microbeads which has no specific binding
capacity for mouse IgG is included in the mixture.
These beads mimic cells with different antigen densi-
ties and they serve as a set of standards to calibrate
the fluorescence scale of the flow cytometer in units
of antibody binding capacity (ABC).18,19 The calcula-
tion of ABC is based on the evaluation of the peak
channel expressed by cells and different population of
microbeads. The minimum detection threshold of
the instrument corresponds to the ABC value for the
blank beads, and provides information on the sensi-
tivity of the flow cytometer in detecting fluorescence
signals.24
For each sample, the ABC value of the isotypic con-
trol was subtracted from the ABC value of the posi-
tive cell population.
MESF calculation (indirect staining)
To evaluate CD34 positivity in AML samples, we
used quantitative microbead calibration standards
(Quantum 26p beads, Flow Cytometry Standard
Corp., purchased from Walter Occhiena srl, Turin,
Italy). The calculation of MESF is based on the eval-
uation of the peak channel expressed by cells and dif-
ferent population of microbeads. The value for the
slope, intercept, and correlation coefficient allow the
calculation of a regression line, which gives informa-
tion on the linearity and stability of the instrument
response, the noise level of the flow cytometer, the
MESF values of the stained and unstained cells, the
resolution indices for fluorescence, and the coeffi-
cient of variation (CV) of microbeads’ fluorescence.
For each sample, the MESF value of the isotypic
control was subtracted from the MESF value of the
positive cell population.
CFU assays 
The colony-forming unit granulocyte-macrophage
(CFU-GM), CFU- GEMM, and BFU-E assays were
performed before and after cryopreservation by plat-
ing 1105 mononuclear cells/plate. Cells were cul-
tured in 35 mm diameter standard tissue culture
dishes (Flow) containing 0.9% methylcellulose
(MethoCult H4230; Stem Cell Technologies, Van-
couver, Canada), 30% pretested FBS, 1% pre-tested
BSA, 10–4 M 2-mercaptoethanol, supplemented with
10% supernatant of the 5637 cell line and 1 U/mL
human urinary erythropoietin. The cells were cultured
for 14 days at 37°C in a humidified atmosphere of
5% CO2 in air. After 14 days of culture, colonies of
more than 50 cells were scored under an inverted
microscope. All cultures were performed in triplicate.
Assessment of cell viability and FAS antigen
expression by flow cytometry
The assessment of cell viability was made with a
Facscan flow cytometer (Becton-Dickinson). Cells
were stained with either propidium iodide solution
(50 µg/mL) or 7-ADD nucleic acid dye.22
Expression of FAS antigen was evaluated on PBM-
NC using the DX2-FITC MoAb (anti-FAS from Ben-
der, Austria) in combination with PE-conjugated
class I, II and III CD34 MoAbs. Cell viability and FAS
expression were evaluated before and after cryop-
reservation.
Statistical analysis 
Expression of class I,II and III CD34 epitopes and
counts of CFU-GM, CFU-GEMM, BFU-E and of other
biological parameters were compared using paramet-
ric and non-parametric statistics (paired Student's t
test, Wilcoxon’s test, linear regression model, multi-
variate regression analysis). When pertinent one way
analysis of variance (ANOVA) and chi square or Fish-
er’s tests were used to compare means and frequencies.
Results
Determination of CD34+ counts for epitope
class I-, II-, and III-reactive MoAbs in fresh and
cryopreserved PBPC
Effects of short-term cryopreservation (90 days
storage) on the expression of CD34 antigens for class
I, II, and III reactive MoAbs are shown in Table 1.
Flow cytometry results showed that class III and class
II CD34+ counts were higher in cryopreserved PBPC
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preparations than fresh cells, while a significant
reduction was observed in class I CD34+ counts
resulting from freezing/thawing procedures and use
of two out of three class I-reactive MoAbs, as com-
pared with pre-cryopreservation values (Table 2). The
number of positive events detected in the negative
controls samples was less than 1% in all cases exam-
ined. As previously mentioned (see Design and Methods
section: flow cytometry analysis of class I, II,and III
CD34 epitopes), viable cells were identified using a
nucleic acid dye staining method (propidium iodide
or 7-AAD) (Figure 1).
The quantitative analysis of CD34 antigens
showed that the cryopreservation procedures
induced a significant increase in ABC values for class
Table 1. Distribution of CD34 epitope classes in PBPC
before and after cryopreservation (direct immunofluores-
cence).*
MoAb Pre-cryo- p value Post-cryo-
preservation preservation 
HPCA-2 (FITC) class III 2.9±3.2 < 0.01 4.7±5.6
HPCA-2 (PE) class III 3.0±3.3 < 0.01 5.0±5.7
581 (FITC) class III 2.6±3.1 < 0.05 4.4±4.6
581 (PE) class III 2.7±3.3 < 0.05 4.6±4.7
QBEND-10 (PE) class II 2.7±3.3 ns 4.2±4.8
BI3C5 (PE) class I 1.7±0.7 < 0.05 1.1±1.4
ICH3 (PE) class I 2.3±2.7 ns 2.0±3.6
IMMU-133 (PE) class I 1.7±1.0 ns 1.8±1.6
*Percentage of positive cells expressed as mean±standard deviation (SD)
ns = not significant (paired test).
Table 2. Percent variation of CD34 cell positivity for the
various CD34  MoAbs after cryopreservation (direct immu-
nofluorescence).
Class III Class II Class I
HPCA-2 HPCA-2 581 581 QBEND-10 ICH3 BI3C5 Immu-133
(FITC) (PE) (FITC) (PE) (PE) (PE) (PE) (PE)
+62% +66% +69% +70% +55% - 8% - 35% no variation
Figure 1. Flow cytome-
try analysis of fresh (A,
B) and cryopreserved
(C,D) PBSC obtained
from patients with non-
Hodgkin’s lymphoma.
Viable CD34+ cells were
identified and quantified
using the cell viability
dye 7-AAD  in combina-
tion with CD34 epitope
class III, II, and I- reac-
tive MoAbs. Simply Cel-
lular beads were used
for the calculation of
ABC units, i.e. number
of antigenic determi-
nants expressed by
CD34+ progenitors
stained with the various
CD34 MoAbs. 
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III and class II CD34 MoAbs (Table 3). However,
compared to baseline values (pre-cryopreservation),
the antigen density expressed by thawed PBPC
labeled with class I CD34 MoAbs was only slightly
increased (ICH3 MoAb) or even decreased with the
remaining two class I-reactive MoAbs (BI3C5 and
Immu-133 MoAbs) (Table 3) (Figure 1).
The clonogenic capacity of PBPC before cryop-
reservation and after thawing was evaluated by
means of standard 14-day culture assays. These data
are shown in Table 4. A comparative analysis of the
effects of cryopreservation on CD34 epitope expres-
sion and numbers of CFU derived from PBPC aphere-
sis products showed a concomitant decrease in class
I CD34+ counts and in BFU-E colony production
(Table 4).
The slight increase in the percentage of CD34+ cells
detected after cryopreservation was correlated to a
concomitant decrease in the number of more mature
myeloid cells (CD15+, CD13+, CD33+) (data not
shown).
Effects of cryopreservation on cell viability were
evaluated by flow cytometry using a multiparameter
staining approach. The mean cell viability (±SD)
decreased from 99.3±2.1% (pre-cryopreservation val-
ues) to 84.2±14.2% after three months of cryo-
preservation (Table 5). Table 5 also shows results
derived from the analysis of either FAS (CD95) anti-
gen expression or DNA staining in CD34-expressing
cells labeled with CD34 epitope class I, II, and III-
reactive MoAbs. 
Determination of CD34+ counts for epitope
class I-, II-, and III-reactive MoAbs in fresh and
cryopreserved AML blasts
Compared to pre-cryopreservation values, a reduc-
tion in class I CD34 epitope expression was also
found in thawed CD34+ blasts obtained from 14
patients with acute myeloid leukemia (AML), who
were analyzed using a larger series (#17) of CD34
epitope class I, II, and III reactive MoAbs (Table 6).
In fact, the reactivity of two out of 4 class I-reactive
MoAbs was decreased after frozen storage at –80°C,
thus confirming data derived from the analysis of the
effects of thawing procedures on the reactivity of
PBPC towards the various CD34 MoAbs. In contrast,
the cytofluorimetric analysis of acute leukemic cells
after frozen storage at –80°C for three months
showed that class III CD34+ counts increased in com-
parison to those found on fresh cells.
The quantification of CD34 antigens showed that
our flow cytometry analysis on frozen-thawed AML
cells was associated with a significant increase in ABC
values for several class III and class II CD34 MoAbs.
An increase in ABC values was also observed in
thawed AML cells stained with three out of 4 class I
CD34 MoAbs, as compared with corresponding
results from fresh aliquots. Antigen density was
decreased in cryopreserved cells labeled with 14G3
class I MoAb, in comparison to those obtained from
the fresh samples (Table 6).
Discussion
In this paper we evaluated the effects of short-term
cryopreservation (3 month storage) on class I, II and III
CD34 epitope expression in a series of leukapheresis
products from lymphoma patients and leukemic sam-
Table 3. Flow cytometry quantification of antigen expression
of CD34 epitope class I, II, and III- reactive MoAbs in fresh
and cryopreserved PBPC (direct immunofluorescence).
MoAbs Pre-cryo- Post-cryo- p value
preservation preservation
(ABC/cell  x 103)
HPCA-2 (FITC) class III 140±48 223±76 p < 0.05
HPCA-2 (PE) class III 60±25 96±31 p < 0.05
581 (FITC) class III 53±14 81± 85 ns
581 (PE) class III 13.1±5.7 14±6.2 ns
QBEND-10 (PE) class II 20±7.8 25±11 ns
BI3C5 (PE) class I 54± 25 50±38 ns
ICH3 (PE) class I 3.5±1.6 5.0±2.5 ns
IMMU-133 (PE) class I 9.4±4.2 8.7±2.6 ns
Data are expressed as ABC (Antibody Binding Capacity) values
(mean±SD)ns = not significant (paired test).
Table 4. Clonogenic capacity (mean ± SD) of PBPC before
and after cryopreservation.
Pre-cryo-  p value Post-cryo-
preservation preservation
CFU-GM/105 cells 144±47 ns 115±64
CFU-GEMM/105 cells 12±9 ns 9±11
BFU-E/105 cells 113±79 ns* 73±81
Data are expressed as mean±SD; ns = not significant value (paired test).
*p < 0.01 comparing a patient subgroup (#12 cases), characterized by a
significant decrease in the expression of two class-I reactive MoAbs (ICH3
and BI-3C5).
Table 5. Fas expression and number of dead cells in CD34-
expressing cells stained with class I, II and III-reactive
MoAbs.
MoAbs used % of double-positive cells*
FAS-FITC/HPCA-2-PE 8.1±7.2
HPCA-2-PE/ nucleic acid dye (7-AAD) 7.3±9.2
FAS-FITC/Q-BEND 10- PE 13.4±12.8
Q-BEND 10- PE/nucleic acid dye (7-AAD) 11.5±9.9 
FAS-FITC/IMMU-133- PE 21.3±16.6
IMMU-133- PE/nucleic acid dye (7-AAD) 20.0±17.7
Data are expressed as percent of  the total CD34-expressing cells (mean±SD).
ples from CD34+ acute myeloid leukemia.
In previous studies, many groups including ours
have shown a great variability in results obtained
within and between the CD34 MoAb classes in prog-
enitor cells taken from bone marrow, PBPC, umbili-
cal cord blood, and acute leukemia samples.19, 28-35
On the basis of these data, many authors have pos-
tulated that the classification into three epitope class-
es could underestimate the extent of antigenic, epi-
topic diversity on the extracellular domains of CD34
molecule. Moreover, data derived from cross-block-
ing studies using several CD34 MoAbs, and the find-
ing that some class II CD34 MoAbs (ICH3, My10,
MD34.1, MD34.2, MD34.3, and 9069) were slight-
ly sensitive to neuraminidase, provide evidence of fur-
ther epitope variation within the three major classes
defined by enzymatic cleavage.2,6 Recent data have
also shown that high endothelial venules selectively
lack class I CD34 epitope, while class II and class III
epitopes are expressed.2,6 Since the biological signif-
icance of the distribution of class I, II and III epitopes
on different CD34+ subpopulations is still uncertain,
we thought it worthwhile to see whether cryopreser-
vation modifies the distribution of different CD34
epitope classes in both normal progenitors and acute
myeloid leukemic blasts.
In this study we have demonstrated that class III
and class II CD34 epitopes (differentially resistant to
enzymatic cleavage with neuraminidase, chymopa-
pain and glycoprotease) are better preserved than
class I epitope — sensitive to degradation — after cell
exposure to cryoprotectant DMSO and the freezing-
thawing procedures. CFU assays have also shown a
concomitant decrease in class I CD34+ counts and in
the BFU-E colony production, suggesting that the
class I epitope recognized by both the CD34 MoAb
ICH3 and BI3C5 may identify a subset of hemopoi-
etic progenitors committed to erythroid lineage.
From a theoretic point of view, cell sorting of class
III+/class I-negative CD34+ cells and their subsequent
culture would give evidence that BFU-E and class I
expression are linked. However, it must be said that
these cells cannot be reliably identified using a cell
sorter or other techniques for a number of reasons,
as reviewed elsewhere.2,37
A reduction in class I and class II CD34 epitope
expression was also found in CD34+ blasts obtained
from 14 patients with acute myeloid leukemia (AML),
who were analyzed using a larger series (#17) of
CD34 epitope class I, II, and III reactive MoAbs.
The slight increase in the percentage of CD34+ cells
after cryopreservation was correlated to a concomi-
tant decrease in the number of more mature myeloid
cells (CD15+, CD13+, CD33+). As far as the increase
in the antibody binding capacity (ABC) observed in
cryopreserved cells stained with CD34 epitope class
III reactive MoAbs is concerned, many explanations
have been offered by authors. Recent studies have
shown that class I and class II MoAbs cannot be
labeled with charged fluorochromes such as FITC,
because of the presence of a large number of acid
residues near the binding site of the antibody. Fur-
thermore, class I and class II MoAbs have a strong
negative charge, and their conjugation to negatively
charged fluorochromes such as FITC induces a sig-
nificant reduction in the binding affinity of the anti-
body.37 As a consequence, class I and class II-reactive
MoAbs should be labeled with fluorochromes such
as PE in order to obtain the most reliable results. The
fact that FITC is the most negatively charged fluo-
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Table 6. Flow cytometry analysis of CD34 epitope class I,II,
and III reactive MoAbs in fresh and cryopreserved acute
leukemic blasts obtained from CD34+ acute leukemias (indi-
rect immunofluorescence).
MoAb pre-cryo- post-cryo-
(epitope class) preservation% * preservation% * p value
MESF/cell x103 ° MESF/cell x103°
CD34-9F2 (III) 38.9±34.4 35.9±24 ns  
149±384 172±200 ns
8G12 (III) 54.8±30.7 51.7±22.3 ns 
248±414 237±462 ns
581 (III) 58.3±31.6 62.4±22.8 ns 
395±678 462±478 p < 0.05
553 (III) 58.2±31.8 63.4±22.4 ns 
409±669 427±405 ns
563 (III) 60.0±30.6 64.9±22.6 ns 
437±697 446±460 ns
QBEND-10 (II) 55.0±29.5 60.6±23.1 ns 
347±603 448±501 ns
43A1 (II) 27.9±34.7 28.8±29.5 ns
6.0±16.1 94±214 p < 0.05
MD34.3 (II) 56.8±30.3 61.5±25.0 ns
290±561 329±363 ns 
MD34.1 (II) 52.6±28.9 52.9±24.6 ns 
108±193 225±232 p < 0.01
MD34.2 (II) 56.8±30.3 62.2±24.6 ns 
276±531 335±373 ns
4A1 (II) 54.8±30.2 54.8±25.8 ns  
135±237 124±193 ns
9066 (II) 50.5±30.7 54.5±23.4 ns
119±207 119±168 ns
9069 (II) 48.3±30.4 50.2±25.7 ns
92±175 105±150 ns
Immu-133 (I) 50.4±30.0 46.4±20.2 p < 0.05 
115±172 290±340 p < 0.01
Immu-409 (I) 14.5±32.1 4.7±13.6 p < 0.05
1.4±3.2 22±9 p < 0.05
14G3 (I) 53.7±30.4 53.4±19.2 ns  
163±336 119±145 p < 0.05
BI3C5 (I) 34.4±32.1 36.7±23.4 ns  
6.4±9.2 147±205 p < 0.01
*Data are expressed as mean percentage±SD; °data are expressed as
mean±SD; MESF = molecular equivalent of soluble fluorochrome; ns = not
significant (paired test).
rochrome may explain the finding that higher ABC
values were detected in samples analyzed using FITC-
conjugated class III MoAbs, than in those using PE-
labeled CD34 MoAbs.37
The large variation in antigen density observed in
frozen-thawed CD34+ cells could be due to a number
of additional factors, such as poor reproducibility
and unreliability of Simply Cellular beads in detecting
CD34 surface antigen expression in cryopreserved
cells, the differences in antibody binding affinities, as
well as the lysis procedure used in this study. Recent
data have shown that binding of CD34 MoAbs could
be affected by lysis and fixation procedures, and that
the binding of the class I antibody Immu-133 was
most markedly decreased.38-40 In a study by Basso et
al. the percentage of CD34 positivity obtained with
NH4Cl or with Q-Lyse lysing solution was significantly
higher than that obtained with FACS lysing solution
(up to eight times higher in cord blood).39 On the
basis of these data, it cannot be excluded that the
lysis methodology may interfere with the binding of
CD34 MoAbs to the cells examined in our study. As
far as the antibody binding affinities are concerned,
it should be take into account that the three epitope
classes are chemically and physically distinct, and
that the binding capacities of the various CD34
MoAbs, either before or after conjugation with dif-
ferent fluorochromes, rely on the form of the MoAb
and on the type of the specimen analyzed.37 It is note-
worthy that class II MoAbs are considered by some
authors to be the reagents of choice for positive selec-
tion of CD34 progenitors, since the epitopes detect-
ed by these MoAbs are very close to the NH2 termi-
nus of CD34 protein, and are contained on a stretch
of linear amino acid sequence that does not directly
involve sugars.6
Regarding the reduction of class I CD34 epitope, it
can be hypothesized that the freezing procedure
and/or use of DMSO may either damage a CD34
subset, or induce distinct alterations of the CD34 gly-
coprotein, possibly causing a reduction in their
immunoreactivity with some CD34 MoAbs. Addi-
tional factors which might affect the reactivity of class
I-reactive MoAbs may be lysis/fixation procedures, as
well as differences in antibody binding affinities of
some class I-reactive CD34 MoAbs (BI3C5, ICH3).
In conclusion, this study has shown that exposure
to the cryoprotectant DMSO and freezing/thawing
procedures modify the distribution of CD34 epitopes
as well as the clonogenic capacity of PBPCs from nHL
patients, and CD34+ blasts from AML. These find-
ings need to considered when selecting CD34 MoAbs
for enumeration and positive selection of stem/prog-
enitor cells for research and clinical purposes.41
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